Form 4: Kiromic Biopharma Director Ralston Reports Acquisition of $2 Million Convertible Note

Director Shannon Ralston reports acquiring a $2 million Senior Secured Convertible Note in Kiromic Biopharma on June 3, 2024.

Summary

• On June 3, 2024, Shannon Ralston, a director of Kiromic Biopharma, Inc., acquired a $2,000,000 Senior Secured Convertible Note.
• The note bears interest at 25% and is subject to a 19.99% blocker.
• The conversion price of the note is $2.5.
• The note is convertible into 800,000 shares of common stock.
• The note matures on June 3, 2025.
• Ralston beneficially owns an aggregate of $19,239,703 principal amount of Senior Secured Convertible Notes through S.hield Cap1tal Funding LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports a transaction. The high interest rate on the convertible note could be a concern, but the director's investment could also be seen as a sign of confidence.

Risks

• The high interest rate of 25% on the convertible note could indicate a higher risk associated with Kiromic Biopharma's financial situation.
• The 19.99% blocker on the convertible note may limit the extent of conversion to common stock.

Industry Context

Form 4 filings are standard disclosures for insiders, such as directors, officers, and principal stockholders, when they trade in their company's stock. This filing indicates a transaction involving a convertible note, which is a common financing instrument in the biopharmaceutical industry, especially for companies in the development stage.

Comparison to Industry Standards

• Convertible notes are frequently used in the biopharmaceutical industry to raise capital, especially by companies that are pre-revenue or have limited operating history.
• The terms of convertible notes, such as interest rates and conversion prices, can vary widely depending on the company's financial health, growth prospects, and overall market conditions.
• A 25% interest rate is relatively high, suggesting that Kiromic Biopharma may have had to offer more attractive terms to secure the financing.
• Comparable companies in the biotech space, such as Celldex Therapeutics or Bellicum Pharmaceuticals, have also utilized convertible notes as a financing mechanism.

Stakeholder Impact

• The acquisition of a convertible note by a director could be viewed positively by shareholders as it demonstrates confidence in the company's future.
• The terms of the convertible note, including the interest rate and conversion price, could impact the company's financial performance and shareholder value.

Key Dates

Keywords

Kiromic Biopharma, Convertible Note, Form 4, Ralston, Director, KRBP, Acquisition, Secured Note